Phase 3 Trial Paused for CP101 in Recurrent C. difficle Infection
March 11th 2022Finch was still able to continue dosing patients in its past-ongoing PRISM-EXT phase 2 open-label trial of CP101 in recurrent CDI, because the CP101 lots used for PRISM-EXT were manufactured from material donated prior to December 1, 2019.
Read More